IL-YANG Pharmaceutical developed the cytokine material that has a market worth in excess of approximately $65 billion and launched 4 types of research reagents. Moreover, it filed the application for the functions and capabilities that could become apparent based on the change of form and applications after conducting the research and verification. The 4 types of research reagents, which were launched by IL-YANG Pharmaceutical, will be used in a variety of applications for bio-drug development in global medical community to cure intractable diseases. IL-YANG Pharmaceutical is proceeding with the research into the various functions of cytokine with an aim to develop the nation’s first cytokine treatment drug as the multinational pharmaceutical companies are recently spurring the development of cytokine-based drugs for the treatment of intractable diseases, and furthermore, is on track to develop the production process needed to put the products onto the market.

Cytokine, one of the proteins inside the body, is a substance involved in human signal transmission, stimulates or inhibits human body's immune system, and induces the production of antibodies that combat the external antigen to control and adjust the defense system of human body. In addition, cytokine is a substance necessary for congenital and adaptive immune response and has wide applications in R&D, such as anti-cancer immunotherapy, rheumatoid arthritis, hematopoietic function, recovery of tissue, treatment of brain disorders, cell growth, etc., and therefore is considered the best options for BIO drugs used to treat intractable diseases.

Along with that, IL-YANG Pharmaceutical is accelerating its drive to develop protein and peptide drugs based on its patented peptide material. Peptide has low biological toxicity and excellent selectivity and is easy to operate. Furthermore, peptide can be chemically synthesized and therefore can be easily researched and applied in various fields such as the medicine, new materials, nano science, molecular imaging, drug delivery, etc. For those reasons, the proportion of peptide drugs approved by the FDA has increased rapidly.